(Q44150295)

English

Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab

scientific article published on 10 June 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

W J F M van der Velden

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

T Mori

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

W B C Stevens

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A F J de Haan

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

F F Stelma

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

N M A Blijlevens

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J P Donnelly

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

language of work or name

0 references

publication date

10 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1465-1471

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Post-transplant lymphoproliferative disorder: a review

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

How I treat EBV lymphoproliferation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Intestinal damage determines the inflammatory response and early complications in patients receiving conditioning for a stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Neutropenia after rituximab treatment: new insights on a late complication

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

21 January 2018

Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.84

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2013.84

1 reference

https://api.fatcat.wiki/v0/release/ra3cfopxrrcbhdexlrktiiofby

30 July 2022

based on heuristic

mapped directly with Wikidata item

Dimensions Publication ID

0 references

release_ra3cfopxrrcbhdexlrktiiofby

1 reference

https://api.fatcat.wiki/v0/release/ra3cfopxrrcbhdexlrktiiofby

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/ra3cfopxrrcbhdexlrktiiofby

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44150295&oldid=2206466102"